1. Home
  2. MAIA vs MGLD Comparison

MAIA vs MGLD Comparison

Compare MAIA & MGLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MAIA
  • MGLD
  • Stock Information
  • Founded
  • MAIA 2018
  • MGLD 1996
  • Country
  • MAIA United States
  • MGLD United States
  • Employees
  • MAIA N/A
  • MGLD N/A
  • Industry
  • MAIA Biotechnology: Pharmaceutical Preparations
  • MGLD Finance/Investors Services
  • Sector
  • MAIA Health Care
  • MGLD Finance
  • Exchange
  • MAIA Nasdaq
  • MGLD Nasdaq
  • Market Cap
  • MAIA 46.7M
  • MGLD 41.9M
  • IPO Year
  • MAIA 2022
  • MGLD N/A
  • Fundamental
  • Price
  • MAIA $2.15
  • MGLD $0.89
  • Analyst Decision
  • MAIA
  • MGLD
  • Analyst Count
  • MAIA 0
  • MGLD 0
  • Target Price
  • MAIA N/A
  • MGLD N/A
  • AVG Volume (30 Days)
  • MAIA 79.7K
  • MGLD 15.8K
  • Earning Date
  • MAIA 05-13-2025
  • MGLD 05-12-2025
  • Dividend Yield
  • MAIA N/A
  • MGLD N/A
  • EPS Growth
  • MAIA N/A
  • MGLD N/A
  • EPS
  • MAIA N/A
  • MGLD N/A
  • Revenue
  • MAIA N/A
  • MGLD $32,057,000.00
  • Revenue This Year
  • MAIA N/A
  • MGLD N/A
  • Revenue Next Year
  • MAIA N/A
  • MGLD N/A
  • P/E Ratio
  • MAIA N/A
  • MGLD N/A
  • Revenue Growth
  • MAIA N/A
  • MGLD N/A
  • 52 Week Low
  • MAIA $1.40
  • MGLD $0.70
  • 52 Week High
  • MAIA $5.99
  • MGLD $2.10
  • Technical
  • Relative Strength Index (RSI)
  • MAIA 70.43
  • MGLD 46.17
  • Support Level
  • MAIA $1.51
  • MGLD $0.81
  • Resistance Level
  • MAIA $1.61
  • MGLD $0.95
  • Average True Range (ATR)
  • MAIA 0.12
  • MGLD 0.10
  • MACD
  • MAIA 0.06
  • MGLD 0.00
  • Stochastic Oscillator
  • MAIA 90.91
  • MGLD 57.27

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

About MGLD The Marygold Companies Inc.

The Marygold Companies Inc is a holding company that intends to focus on financial services. It is currently directing its investments towards financial services and the emerging Fintech space.

Share on Social Networks: